Literature DB >> 27443829

Evaluation of a Pharmacist and Nurse Practitioner Smoking Cessation Program.

Zubair Afzal1, Elizabeth Pogge2, Virginia Boomershine3.   

Abstract

PURPOSE: To evaluate the efficacy of a smoking cessation program led by a pharmacist and a nurse practitioner.
METHODS: During a 6-month period, patients attended 7 one-on-one face-to-face smoking cessation counseling sessions with a pharmacist and 1 to 2 one-on-one face-to-face smoking cessation counseling sessions with a nurse practitioner. The primary outcome was smoking cessation point prevalence rates at months 1, 3, and 5 post-quit date. Secondary outcomes included medication adherence rates at months 1, 3, and 5 post-quit date, nicotine dependence at baseline versus program end, and patient satisfaction.
RESULTS: Nine (47%) of 19 total participants completed the program. Seven of the 9 patients who completed the program were smoke-free upon study completion. Point prevalence rates at months 1, 3, and 5 post-quit date were 66%, 77%, and 77%, respectively, based on patients who completed the program. Medication adherence rates were 88.6%, 54.6%, and 75% at months 1, 3, and 5 post-quit date, respectively. Based on the Fagerstrom test, nicotine dependence decreased from baseline to the end of the study, 4.89 to 0.33 ( P < .001). Overall, participants rated the program highly.
CONCLUSION: A joint pharmacist and nurse practitioner smoking cessation program can assist patients in becoming smoke-free.

Entities:  

Keywords:  nurse practitioner; pharmacist; smoking cessation

Mesh:

Year:  2016        PMID: 27443829     DOI: 10.1177/0897190016659221

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  5 in total

1.  What Factors Influence Non-Adherence to the Smoking Cessation Program?

Authors:  Nagihan Durmuş Koçak; Ülkü Aka Aktürk
Journal:  Turk Thorac J       Date:  2019-04-01

2.  Screening, Brief Intervention, and Referral to Treatment in a Retail Pharmacy Setting: The Pharmacist's Role in Identifying and Addressing Risk of Substance Use Disorder.

Authors:  Brian C Shonesy; Donald Williams; Damian Simmons; Erin Dorval; Stuart Gitlow; Richard M Gustin
Journal:  J Addict Med       Date:  2019 Sep/Oct       Impact factor: 3.702

3.  Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST).

Authors:  Gentry Carter; Ziji Yu; M Aryana Bryan; Jennifer L Brown; T Winhusen; Gerald Cochran
Journal:  Addict Behav       Date:  2021-11-10       Impact factor: 3.913

4.  Incorporating Oral Health Considerations for Medication Management in Care Transitions.

Authors:  Kimberly A Sanders; Christine L Downey; Anita Yang; Brooke K Baker
Journal:  Pharmacy (Basel)       Date:  2020-04-16

5.  A Pragmatic Pilot Cluster-Randomized Study of Tobacco Screening and Smoking Cessation Program for Community Pharmacies in Japan: FINE Program.

Authors:  Mitsuko Onda; Michiko Horiguchi; Masayuki Domichi; Naoki Sakane
Journal:  J Smok Cessat       Date:  2021-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.